GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

GAZYVA + bendamustine followed by GAZYVA monotherapy demonstrated greater overall response rates vs bendamustine alone 1

Best overall response* rates with GAZYVA + bendamustine followed by GAZYVA monotherapy vs bendamustine alone were 78.7% vs. 74.7%, respectively

GAZYVA GADOLIN Secondary Endpoint: CR and PR Chart